Insider transaction 📈 Stocks 🌍 United States

NeOnc CEO Amir Heshmatpour Adds 80,000 Shares in Open-Market Purchases

NeOnc CEO Amir Heshmatpour increased his stake in the company by 80,000 shares, bringing his total 2026 personal investment to $1.11 million ahead of upcoming clinical data presentations.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: NCTH ↑ 4/10 (65% confidence).

📊 Affected Assets (1)

NCTH
Bullish 🤖 65%
📅 Short-term 🌍 US · Explicit

CEO Amir Heshmatpour bought 80,000 shares on the open market on November 5, 6 and 9, 2026 for $269,082 (about $3.36 per share), bringing his 2026 open-market purchases to 271,000 shares for roughly $1.11 million of personal funds. Insider buying at these levels is typically read as a management confidence signal for a clinical-stage biotech, and it comes just ahead of the November 13 Society for Neuro-Oncology data presentations. However, the filing itself changes nothing about the company's cash position or clinical results, so the effect is a sentiment nudge rather than a fundamental catalys

Catalysts
  • ▲ CEO purchased 80,000 shares for $269,082 on November 5, 6 and 9, 2026
  • ▲ 2026 open-market purchases total 271,000 shares (~$1.11 million), 191,000 of them after the August 12 Phase 2a topline announcement
Risk Factors
  • ▼ NEO100 Phase 2a was a single-arm, open-label study not powered as a confirmatory trial
  • ▼ Neither NEO100 nor NEO212 is approved by any regulatory authority and no approval pathway is assured

🧭 Full analysis of these assets

🎯 Key Takeaways

  • CEO Amir Heshmatpour purchased 80,000 shares between November 5 and November 9, 2026, at an average price of $3.36 per share.
  • Total 2026 open-market purchases by the CEO reached 271,000 shares for approximately $1.11 million.
  • NeOnc is scheduled to present clinical data for its NEO100 and NEO212 programs at the Society for Neuro-Oncology Annual Meeting on November 13.
  • The Phase 2a study of NEO100 reported a six-month progression-free survival rate of 48.9%.

📝 Executive Summary

NeOnc Technologies Holdings CEO Amir Heshmatpour purchased 80,000 shares of company stock for $269,082 in early November. This brings his total 2026 open-market acquisitions to 271,000 shares, representing an investment of approximately $1.11 million. The move precedes the company's scheduled data presentations for its NEO100 and NEO212 programs at the Society for Neuro-Oncology Annual Meeting.

❓ FAQ

How much has the NeOnc CEO invested in the stock this year?

He has bought 271,000 shares on the open market across April, May, August, September and November 2026, totaling approximately $1.11 million of his own money, including 80,000 shares for $269,082 in early November at a weighted average of about $3.36 per share.

Why is the CEO's buying seen as positive for the share price?

Open-market purchases with personal funds, repeated since the August 12 Phase 2a topline results, signal that the CEO believes in the long-term potential of NEO100 and NEO212, which can support investor confidence, though it does not change the company's cash or approval outlook.